The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer

@inproceedings{Powles2011TheSA,
  title={The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer},
  author={Thomas B Powles and Irfan A. Kayani and Christian U Blank and Simon Chowdhury and Simon Horenblas and John Peters and Jonathan Shamash and Noureen Sarwar and K. Boletti and Anju Sadev and Terrence O'Brien and Daniel Berney and Luis Beltr{\'a}n and John B A G Haanen and Axel Bex},
  booktitle={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2011}
}
BACKGROUND The safety and efficacy of upfront sunitinib, before nephrectomy in metastatic clear cell renal cancer (mCRC), has not been prospectively evaluated. METHODS Two prospective single-arm phase II studies investigated either two cycles (study A: n = 19) or three cycles (study B: n = 33) of sunitinib before nephrectomy in mCRC. RESULTS Overall, 38 of 52 (73%) of patients obtained clinical benefit (by RECIST) before surgery. The partial response rate of the primary tumour was 6… CONTINUE READING